The Chemours Company (NYSE:CC) Shares Sold by Quadrature Capital Ltd

Quadrature Capital Ltd cut its stake in The Chemours Company (NYSE:CC - Free Report) by 67.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,624 shares of the specialty chemicals company's stock after selling 23,879 shares during the quarter. Quadrature Capital Ltd's holdings in Chemours were worth $236,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Matrix Trust Co acquired a new position in shares of Chemours during the 3rd quarter worth approximately $25,000. Blue Trust Inc. raised its stake in shares of Chemours by 166.9% during the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock worth $26,000 after buying an additional 731 shares during the period. Truvestments Capital LLC purchased a new stake in shares of Chemours during the third quarter worth approximately $35,000. Brooklyn Investment Group purchased a new stake in shares of Chemours during the third quarter worth approximately $37,000. Finally, Signaturefd LLC increased its position in shares of Chemours by 163.7% during the third quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company's stock worth $40,000 after purchasing an additional 1,216 shares in the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Trading Down 6.5 %

Shares of Chemours stock traded down $1.37 during trading hours on Wednesday, hitting $19.80. The company's stock had a trading volume of 1,406,101 shares, compared to its average volume of 1,574,216. The Chemours Company has a twelve month low of $15.10 and a twelve month high of $32.70. The firm has a fifty day moving average of $19.93 and a 200-day moving average of $20.92. The stock has a market cap of $2.96 billion, a price-to-earnings ratio of 39.84 and a beta of 1.80. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. During the same quarter in the prior year, the company posted $0.64 EPS. The company's quarterly revenue was up .9% on a year-over-year basis. Research analysts forecast that The Chemours Company will post 1.35 EPS for the current year.

Chemours Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 5.05%. The ex-dividend date is Friday, November 15th. Chemours's payout ratio is 200.00%.

Analyst Ratings Changes

Several analysts recently commented on the company. Barclays boosted their price target on Chemours from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. Royal Bank of Canada dropped their price target on Chemours from $28.00 to $25.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group dropped their price target on Chemours from $29.00 to $23.00 and set a "neutral" rating for the company in a research report on Tuesday, September 3rd. Morgan Stanley dropped their price target on Chemours from $30.00 to $25.00 and set an "equal weight" rating for the company in a research report on Tuesday, November 5th. Finally, BMO Capital Markets upped their target price on Chemours from $30.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, October 7th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $24.88.

Insider Buying and Selling

In related news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the transaction, the senior vice president now owns 16,645 shares of the company's stock, valued at approximately $343,552.80. This represents a 31.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.47% of the stock is owned by corporate insiders.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.